Tumor Types & Biomarkers
Tumor Types & Biomarkers

Explore clinical guidelines on why, whom and how to test actionable biomarkers in lung, breast, ovarian and prostate cancers.
- Lung Tumor
  
  EGFR
  
  ERBB2 (HER2)
- Breast Tumor
  
  BRCA1/2
  
  ESR1
  
  HER2
  
  PIK3CA/AKT1/PTEN
- Ovarian Tumor
  
  HRD
- Prostate Tumor
  
  HRRm
  
  PTEN
Testing Solutions
Explore Precision Medicine

Explore Precision Medicine

Implement best practices in your workflow and discover how recent advances are optimizing precision medicine.

Realizing the Potential of Precision Medicine

Collaborate across the MDT to address health inequities and optimize testing pathways.
Realizing the Potential of Precision Medicine

Latest Developments in Precision Medicine

Explore recent advances in diagnostic technologies and novel biomarkers to support precision medicine in your practice.
Latest Developments in Precision Medicine
Resources

Resources

Access a range of resources you can apply in your practice.

FAQs

Find answers to frequently asked questions about precision medicine.
FAQs

Find a Testing Lab

Search our directory of major laboratories that perform diagnostic biomarker testing.
Find a Testing Lab

Glossary

Find definitions for the most commonly used terms in precision medicine.
Glossary

Resource Library

Explore our library of videos and downloadable tools to help optimize your practice and inform your patients.
Resource Library

My Favorites

Personalize your learning by creating a bespoke collection of precision medicine resources.
My Favorites
Our Team

Breast cancer
BRCA1/2

BRCA1/2

Jump to:

Clinical Relevance
Testing Recommendations
Prevalence
Role of BRCA1/2
Sample Type Considerations
Diagnostic Assays
Interpreting & Reporting
Testing Challenges
Considerations for Your Practice
Helpful Resources

Testing for Germline BRCA1 and BRCA2 Mutations Can Guide Treatment^1–3

Mutations in BRCA1 and BRCA2 are associated with a high lifetime risk of developing breast cancer.¹ Testing for these mutations in eligible patients with breast cancer can inform preventative, prognostic and therapeutic decisions.^2,3

BRCA1/2, BReast CAncer susceptibility gene 1/2.

BRCA1 and BRCA2 Testing Recommendations Aim to Identify the Risk of Developing Breast Cancer and Inform Treatment¹

Find additional recommendations in the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines^®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate.¹

American Society of Clinical Oncology and the Society for Surgical Oncology (ASCO-SSO) joint germline testing guidelines recommend BRCA1/2 testing in anyone⁷:

With breast cancer ≤65 years of age
Who may be eligible for a PARP inhibitor (regardless of family history)
With a personal history of breast cancer who are without active disease if the result will inform personal risk management or family risk assessment

The American Society of Breast Surgeons (ASBrS) recommend testing anyone with a personal history of breast cancer as well as patients who don’t have a history of disease but meet NCCN Guidelines^® criteria⁸

^aFour or more positive pathologically confirmed lymph nodes if treated with adjuvant chemotherapy; clinical and pathologic stage (CPS) + estrogen receptor status and histologic grade (EG) score of 3 or higher and absence of complete pathologic response following treatment with neoadjuvant chemotherapy.^{1 b}If using a commercial assay for testing, check the manufacturer’s sample requirements.

ASCO, American Society of Clinical Oncology; ASBrS, American Society of Breast Surgeons; BRCA1/2, BReast CAncer susceptibility gene 1/2; CDx, companion diagnostic; CPS, clinical and pathologic stage; EG, histologic grade; FDA, US Food and Drug Administration; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NCCN, National Comprehensive Cancer Network; PARP, poly-ADP ribose polymerase; SSO, Society for Surgical Oncology; TNBC, triple-negative breast cancer.

Around 1 in 10 Patients With HER2-Negative Breast Cancer Have a gBRCA Mutation, Highlighting Implications for Treatment and Genetic Counseling^9–11

HR+/HER2-negative breast cancer accounts for around 60% of patients with gBRCA mutations^9–11

BRCA2 mutations are more common than BRCA1 mutations in HR+/HER2-negative breast cancer¹²

~1 in 10

patients with HER2-negative breast cancer has a gBRCA mutation^9–11

While gBRCA mutations are more prevalent in TNBC, the HR+/HER2-negative subtype is the most common subtype and accounts for the majority of patients with gBRCA mutations^10,13,14

Of those patients with a gBRCA mutation:

HR+

~60%

TNBC

~40%

BRCA1/2, BReast CAncer susceptibility gene 1/2; gBRCA, germline BReast CAncer susceptibility gene; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; TNBC, triple-negative breast cancer.

BRCA1/2 Mutations Can Eventually Lead to Breast Cancer Development¹⁵

Both BRCA and PARP proteins are important for repairing DNA. Mutations in BRCA prevent the proper repair of DNA and may eventually lead to breast cancer development.¹⁵

dummy

BRCA1/2, BReast CAncer susceptibility gene 1/2; DNA, deoxyribonucleic acid; PARP, poly (ADP-ribose) polymerase.

Consider Sample Type and BRCA Mutation Type to Inform Outcomes¹⁶

Germline testing can be performed on blood or saliva/buccal swabs

BRCA mutation type	Sample type	Clinical relevance	Limitations
Germline	Blood, saliva, or buccal swab	May inform familial risk, prognosis, and treatment	Saliva and buccal swab samples do not identify patients with somatic mutations^16,17

Testing tumor tissue and ctDNA does not currently distinguish between somatic and germline mutations

BRCA mutation type	Sample type	Clinical relevance	Limitations
Somatic	Tumor tissue	Determines total mutation status (somatic and germline)¹⁶	Samples can be heterogeneous, containing both malignant and normal cells¹⁸ Does not distinguish between somatic and germline mutations without analyzing non-tumor samples¹⁹
Somatic	Blood (plasma ctDNA)	Use to support tissue testing or when tumor tissue is unavailable²⁰	Mutation profiling is dependent on tumor shedding²¹ Does not distinguish between somatic and germline mutations without confirmatory testing^22,23

Find best practice to address sample limitations.

Browse Testing Solutions

gBRCA1/2 testing may aid your clinical approach: It is no longer just for familial risk assessment^24–27

Past

Present

gBRCA testing used solely for familial risk assessment

gBRCA testing may inform therapy decisions, risk of recurrence, and evaluates familial risk^24,27

BRCA1/2, BReast CAncer susceptibility gene 1/2; ctDNA, circulating tumor DNA; gBRCA1/2, germline BReast CAncer susceptibility gene 1/2.

Diagnostic Assays Screen for and Identify BRCA1/2 Mutations

Testing should include full gene sequencing, deletion/duplication analysis, and detection of known pathogenic/likely pathogenic variants in a Clinical Laboratory Improvement Amendments (CLIA)-certified and/or College of American Pathologists (CAP)-accredited genetic testing laboratory.²⁸ Sanger sequencing is considered the gold standard for detection of genetic mutations.²⁹

Labs offering gBRCA1/2 testing have turnaround times of around 2 weeks^a

FDA-approved tests³⁰

Laboratory	Test name	Sample requirements	Turnaround time (days)
Myriad Genetics	BRACAnalysis CDx^®31,32	Blood: ~7 mL	≤14
Invitae	Common Hereditary Cancers Panel^33–35	Blood (preferred) 3 mL, saliva, buccal swabs, or DNA (5 μg)	10–21

Non-FDA-approved tests

Laboratory	Test name	Sample requirements	Turnaround time (days)
Ambry Genetics	BRCA1 and BRCA2^36,37	Blood: 3–4 cc, Saliva: 1 mL, 2 buccal swabs, 5 μg DNA	6–10
Ambry Genetics	CancerNext^®36,38	Blood: 3–4 cc, Saliva: 1 mL, 2 buccal swabs, 5 μg DNA	14–21
GeneDx	BRCA1/2 Sequencing and Del/ Dup Analysis³⁹	Blood: 2–5 mL, buccal swabs	8–10
GeneDx	Comprehensive Common Cancer Panel⁴⁰	Blood: 2–5 mL, buccal swabs	14
Invitae	BRCA1 and BRCA2 STAT Panel⁴¹	Blood (preferred) 3 mL, saliva	5–12
Myriad Genetics	MyRisk^®42–44	Blood, saliva	7–14

^aThis information is intended as educational and is not intended as a complete list of available testing options. AstraZeneca is not responsible for any test provider and does not endorse any particular diagnostic test. The accuracy and results of diagnostic tests vary, and AstraZeneca shall have no liability arising from such testing. Information provided herein should in no way be considered a guarantee of coverage, reimbursement, or patient assistance. Providers should contact third-party laboratories for information on their patient assistance programs. While diagnostic testing may assist providers in identifying appropriate treatment for patients, the decision and action should be decided by a provider in consultation with the patient. All products are trademarks of their respective holders, all rights reserved.

BRCA1/2, BReast CAncer susceptibility gene 1/2; CAP, College of American Pathologists; CDx, companion diagnostic; CLIA, Clinical Laboratory Improvement Amendments; DNA, deoxyribonucleic acid; FDA, US Food and Drug Administration.

Comprehensive Interpretation and Reporting of Germline BRCA1/2 Test Results is Critical for Informing Treatment Decisions¹⁸

Detecting BRCA1/2 sequence variations may require more than one method

Sequence variations in BRCA1 and BRCA2 fall into three broad categories¹⁸:

Single-nucleotide changes
Small insertion or deletion events (indels)
Large genomic rearrangements (LGRs)

Single-nucleotide changes and indels can be detected by direct Sanger sequencing or NGS¹⁸

LGRs cannot be detected by direct Sanger sequencing

Instead, alternative polymerase chain reaction (PCR)-based techniques (e.g. quantitative PCR, multiplex ligation-dependent probe amplification) are required¹⁸

Whether performing in-house testing or sending to a testing lab, ensure the methodology is comprehensive and includes LGRs and indels.¹⁸

Find a Testing Lab

This information is intended as educational and is not intended as a complete list of available testing options. AstraZeneca is not responsible for any test provider and does not endorse any particular diagnostic test. The accuracy and results of diagnostic tests vary, and AstraZeneca shall have no liability arising from such testing. Information provided herein should in no way be considered a guarantee of coverage, reimbursement, or patient assistance. Providers should contact third-party laboratories for information on their patient assistance programs. While diagnostic testing may assist providers in identifying appropriate treatment for patients, the decision and action should be decided by a provider in consultation with the patient. All products are trademarks of their respective holders, all rights reserved.

BRCA genes can harbor many different types of mutation; therefore, test results may not be a straightforward positive or negative^18,45

Positive

Indicates:

A known actionable mutation has been identified, and the patient is BRCA mutation-positive⁴⁵

May also be called:

Pathogenic, likely pathogenic, deleterious, suspected deleterious^46,47

Negative

Indicates:

No mutation was detected by the testing methodology⁴⁸

Variant of unknown significance (VUS)

Indicates:

A BRCA variant was detected, but the specific variant has not been previously classified as harmful or harmless; the variant has an unknown effect on protein function and risk of disease.^18,45,49 While not clinically actionable at the time of the test, the reporting laboratory may follow up on the clinical relevance of VUS if more information becomes available over time⁴⁷

Treatment decisions should not be made based on a VUS result.

May also be called:

Inconclusive or variant of uncertain significance^45,46,50

Benign variant

Indicates:

A BRCA sequence variant was detected, but the variant is nonpathogenic; treat as BRCA mutation-negative^7,47

May also be called:

Benign variant, likely benign, favor polymorphism^46,47

BRCA1/2, BReast CAncer susceptibility gene 1/2; indels, small insertion or deletion events; LGR, large genomic rearrangement; NGS, next-generation sequencing; PCR, polymerase chain reaction; VUS, variant of unknown significance.

Solutions to BRCA1/2 Testing Challenges Focus on Tissue Sample Quality and Standardization^51,52

Knowing which biomarkers to test for is valuable, but it’s equally important to anticipate common challenges that providers may experience during the testing phase, including:

Tissue sample quality and handling^51,52
- Factors to consider include age of the sample, new vs. archival tissue, DNA yield, tumor content, and primary vs. metastatic site⁵³
The need for a standardized testing workflow⁵²
The need for leadership in the management of the testing program^51,54

Find solutions to common challenges you may face during biomarker testing.

Browse Testing Solutions

Considerations for Your Practice

Implement germline BRCA1/2 testing for appropriate patients with breast cancer, considering guidance from NCCN^®, ASCO-SSO and ASBrS.

View a suite of educational resources that facilitate genetic testing conversations between you and patients with breast cancer at Gene&i.com

Looking for a genetic counselor?

Find a genetic counselor Learn how genetic counseling can be integrated into clinical practice

ASCO, American Society of Clinical Oncology; ASBrS, American Society of Breast Surgeons; BRCA1/2, BReast CAncer susceptibility gene 1/2; NCCN, National Comprehensive Cancer Network; SSO, Society for Surgical Oncology.

AstraZeneca is not affiliated with and does not control these websites. Inclusion of a website on AZPrecisionMed.com does not constitute endorsement of its content by the associated organizations.

Helpful Resources

Check out these featured resources on BRCA biomarker testing in breast cancer.

Add your preferred resources to My Favorites—a personalized list of resources to download and share with your peers or patients.

View My Favorites

dummy

View more resources

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic and Prostate V.2.2025. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 7, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org.
Tung NM and Garber JE. Br J Cancer. 2018;119(2):141–152.
Pujol P, et al. Eur J Cancer. 2021;146:30–47.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Breast Cancer V.6.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 20, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org.
Tischler J, et al. Ann Intern Med. 2019;171(12):925–930.
Myriad Genetics. BRACAnalysis CDx^® Provider Guide. Accessed August 13, 2024. https://myriad-library.s3.amazonaws.com/BRACAnalysis CDx/BRACAnalysis CDx Provider Guide.pdf
Bedrosian I, et al. J Clin Oncol. 2024;42(5):584–604.
The American Society of Breast Surgeons. Consensus Guideline on Genetic Testing for Hereditary Breast Cancer. Accessed August 13, 2024. https://www.breastsurgeons.org/docs/statements/Consensus Guideline on Genetic Testing for Hereditary Breast Cancer.pdf
Winter C, et al. Ann Oncol. 2016;27(8):1532–1538.
Kurian A, et al. J Clin Oncol. 2019;37(15):1305–1315.
Copson E, et al. Lancet Oncol. 2018;19(2):169–180.
Song Y, et al. Cancer. 2020;126(2):271–280.
National Cancer Institute. Cancer Stat Facts: Female Breast Cancer Subtypes. Accessed August 13, 2024. https://seer.cancer.gov/statfacts/html/breast-subtypes.html
Hu C, et al. J Natl Cancer Inst. 2020;112(12):1231–1241.
McLornan DP, et al. N Engl J Med. 2014;371(18):1725–1735.
Cheng HH, et al. J Natl Compr Canc Netw. 2019;17(5):515–521.
Pennington KP, et al. Clin Cancer Res. 2014;20(3):764–775.
Wallace AJ. Eur J Hum Genet. 2016;24(suppl 1):S10–S18.
Raymond VM, et al. J Natl Cancer Inst. 2015;108(4):djv351.
Chang Y, et al. Ther Clin Risk Manag. 2017;13:1363–1374.
Fiala C and Diamandis EP. BMC Med. 2018;16(1):166.
Keller L, et al. Br J Cancer. 2021;124(2):345–358.
Foundation Medicine. FoundationOne^® Liquid CDx technical information. Accessed August 13, 2024. https://assets.ctfassets.net/w98cd481qyp0/3a8jFw3KUjIU3RWPdcT9Ax/dcb2ffd6d8d9a40a65ccf663269cc39a/FoundationOne Liquid CDx Label Technical Info.pdf
Frey MK and Pothuri B. Gynecol Oncol Res Pract. 2017;4:4.
Konecny GE and Kristeleit RS. Br J Cancer. 2016;115(10):1157–1173.
O’Sullivan CC, et al. Front Oncol. 2014;4:42.
Walsh CS. Gynecol Oncol. 2015;137(2):343–350.
Pal T, et al. Genet Med. 2020;22(4):681–685.
Wu H, et al. Gene Ther. 2017;24(10):601–609.
US Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Accessed August 13, 2024. https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools
Myriad Genetics. BRCAnalysis CDx^® Germline Diagnostic Test. Accessed August 13, 2024. https://myriad.com/genetic-tests/bracanalysiscdx-germline-test/
Center for Drug Evaluation and Research. Summary of Safety and Effectiveness Data (SSED). Accessed August 13, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206162Orig1s000OtherR.pdf
Invitae. Invitae Common Hereditary Cancers Panel. Accessed August 13, 2024. https://www.invitae.com/en/physician/tests/01102/
Invitae. Specimen and shipping requirements. Accessed August 13, 2024. https://www.invitae.com/en/specimen-requirements/
US Food and Drug Administration. FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types. Accessed August 13, 2024. https://www.fda.gov/news-events/press-announcements/fda-grants-first-marketing-authorization-dna-test-assess-predisposition-dozens-cancer-types
Ambry Genetics. Specimen Requirements. Accessed August 13, 2024. https://www.ambrygen.com/providers/specimen-requirements
Ambry Genetics. BRCA1 and BRCA2. Accessed August 13, 2024. https://www.ambrygen.com/providers/genetic-testing/23/oncology/brca1-and-brca2
Ambry Genetics. CancerNext^®. Accessed August 13, 2024. https://www.ambrygen.com/providers/genetic-testing/1/oncology/cancernext
GeneDx. BRCA1/2 Sequencing and Del/Dup analysis. Accessed August 13, 2024. https://www.genedx.com/tests/detail/brca1-2-sequencing-and-del-dup-analysis-781
GeneDx. Comprehensive Common Cancer Panel. Accessed August 13, 2024. https://www.genedx.com/tests/detail/comprehensive-common-cancer-panel-778
Invitae. Invitae BRCA1 and BRCA2 STAT Panel. Accessed August 13, 2024. https://www.invitae.com/en/physician/tests/50002/
Myriad Genetics. MyRisk hereditary cancer technical specifications. Accessed August 13, 2024. https://myriad-library.s3.amazonaws.com/technical-specifications/Myriad+Combo+Tech+Specs.pdf
Myriad Genetics. Illuminating hereditary cancer risk with genetic testing. Accessed August 13, 2024. https://myriad-web.s3.amazonaws.com/myRisk/MyRisk_PreTest+PET+FullPage.pdf
Myriad Genetics. MyRisk gene table. Accessed August 13, 2024. https://myriad-web.s3.amazonaws.com/myRisk/Gene+Table.pdf
Committee on Practice Bulletins–Gynecology, Committee on Genetics, Society of Gynecologic Oncology. Obstet Gynecol. 2017;130(3):e110–e126.
Myriad Genetics. BRACAnalysis CDx^® Technical Information. Accessed August 13, 2024. https://s3.amazonaws.com/myriad-web/BRACAnalysisCDxTS.pdf
Richards S, et al. Genet Med. 2015;17(5):405–424.
Ambry Genetics. Hereditary Cancer Testing Patient Guide. Accessed August 13, 2024. https://www.ambrygen.com/file/material/view/1358/Patient_Guide_BRCA1_2_0320_final.pdf
Miller-Samuel S, et al. Semin Oncol. 2011;38(4):469–480.
Stanislaw C, et al. Cancer Biol Med. 2016;13(1):55–67.
Kim ES, et al. J Thorac Oncol. 2019;14(3):338–342.
Compton CC, et al. Arch Pathol Lab Med. 2019;143(11):1346–1363.
Hussain M, et al. Clin Cancer Res. 2022;28(8):1518–1530.
Lim C, et al. Curr Oncol. 2017;24(2):103–110.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Tumor Types & Biomarkers

Explore Precision Medicine

Realizing the Potential of Precision Medicine

Latest Developments in Precision Medicine

Resources

FAQs

Find a Testing Lab

Glossary

Resource Library

My Favorites

Search

BRCA1/2 Mutations in Breast Cancer

Testing for Germline BRCA1 and BRCA2 Mutations Can Guide Treatment1–3

BRCA1 and BRCA2 Testing Recommendations Aim to Identify the Risk of Developing Breast Cancer and Inform Treatment1

Why test

Whom to test

How to test

Why test

Whom to test

How to test

American Society of Clinical Oncology and the Society for Surgical Oncology (ASCO-SSO) joint germline testing guidelines recommend BRCA1/2 testing in anyone7:

The American Society of Breast Surgeons (ASBrS) recommend testing anyone with a personal history of breast cancer as well as patients who don’t have a history of disease but meet NCCN Guidelines® criteria8

Footnotes

Around 1 in 10 Patients With HER2-Negative Breast Cancer Have a gBRCA Mutation, Highlighting Implications for Treatment and Genetic Counseling9–11

HR+/HER2-negative breast cancer accounts for around 60% of patients with gBRCA mutations9–11

~1 in 10

patients with HER2-negative breast cancer has a gBRCA mutation9–11

While gBRCA mutations are more prevalent in TNBC, the HR+/HER2-negative subtype is the most common subtype and accounts for the majority of patients with gBRCA mutations10,13,14

BRCA1/2 Mutations Can Eventually Lead to Breast Cancer Development15

Both BRCA and PARP proteins are important for repairing DNA. Mutations in BRCA prevent the proper repair of DNA and may eventually lead to breast cancer development.15

Consider Sample Type and BRCA Mutation Type to Inform Outcomes16

Germline testing can be performed on blood or saliva/buccal swabs

Testing tumor tissue and ctDNA does not currently distinguish between somatic and germline mutations

Find best practice to address sample limitations.

gBRCA1/2 testing may aid your clinical approach: It is no longer just for familial risk assessment24–27

Past

Present

gBRCA testing used solely for familial risk assessment

gBRCA testing may inform therapy decisions, risk of recurrence, and evaluates familial risk24,27

Diagnostic Assays Screen for and Identify BRCA1/2 Mutations

Labs offering gBRCA1/2 testing have turnaround times of around 2 weeksa

FDA-approved tests30

Non-FDA-approved tests

Comprehensive Interpretation and Reporting of Germline BRCA1/2 Test Results is Critical for Informing Treatment Decisions18

Detecting BRCA1/2 sequence variations may require more than one method

Sequence variations in BRCA1 and BRCA2 fall into three broad categories18:

Single-nucleotide changes and indels can be detected by direct Sanger sequencing or NGS18

LGRs cannot be detected by direct Sanger sequencing

Whether performing in-house testing or sending to a testing lab, ensure the methodology is comprehensive and includes LGRs and indels.18

BRCA genes can harbor many different types of mutation; therefore, test results may not be a straightforward positive or negative18,45

Positive

Indicates:

May also be called:

Negative

Indicates:

Variant of unknown significance (VUS)

Indicates:

Treatment decisions should not be made based on a VUS result.

May also be called:

Benign variant

Indicates:

May also be called:

Solutions to BRCA1/2 Testing Challenges Focus on Tissue Sample Quality and Standardization51,52

Find solutions to common challenges you may face during biomarker testing.

Considerations for Your Practice

Implement germline BRCA1/2 testing for appropriate patients with breast cancer, considering guidance from NCCN®, ASCO-SSO and ASBrS.

Helpful Resources

Subscribe to Emails

Connect With Us

References

Share Resource

AZPrecisionMed.com

What is an AstraZeneca authorised person?

Share Resource

Testing for Germline BRCA1 and BRCA2 Mutations Can Guide Treatment^1–3

BRCA1 and BRCA2 Testing Recommendations Aim to Identify the Risk of Developing Breast Cancer and Inform Treatment¹

American Society of Clinical Oncology and the Society for Surgical Oncology (ASCO-SSO) joint germline testing guidelines recommend BRCA1/2 testing in anyone⁷:

The American Society of Breast Surgeons (ASBrS) recommend testing anyone with a personal history of breast cancer as well as patients who don’t have a history of disease but meet NCCN Guidelines^® criteria⁸

Around 1 in 10 Patients With HER2-Negative Breast Cancer Have a gBRCA Mutation, Highlighting Implications for Treatment and Genetic Counseling^9–11

HR+/HER2-negative breast cancer accounts for around 60% of patients with gBRCA mutations^9–11

patients with HER2-negative breast cancer has a gBRCA mutation^9–11

While gBRCA mutations are more prevalent in TNBC, the HR+/HER2-negative subtype is the most common subtype and accounts for the majority of patients with gBRCA mutations^10,13,14

BRCA1/2 Mutations Can Eventually Lead to Breast Cancer Development¹⁵

Both BRCA and PARP proteins are important for repairing DNA. Mutations in BRCA prevent the proper repair of DNA and may eventually lead to breast cancer development.¹⁵

Consider Sample Type and BRCA Mutation Type to Inform Outcomes¹⁶

gBRCA1/2 testing may aid your clinical approach: It is no longer just for familial risk assessment^24–27

gBRCA testing may inform therapy decisions, risk of recurrence, and evaluates familial risk^24,27

Labs offering gBRCA1/2 testing have turnaround times of around 2 weeks^a

FDA-approved tests³⁰

Comprehensive Interpretation and Reporting of Germline BRCA1/2 Test Results is Critical for Informing Treatment Decisions¹⁸

Sequence variations in BRCA1 and BRCA2 fall into three broad categories¹⁸:

Single-nucleotide changes and indels can be detected by direct Sanger sequencing or NGS¹⁸

Whether performing in-house testing or sending to a testing lab, ensure the methodology is comprehensive and includes LGRs and indels.¹⁸

BRCA genes can harbor many different types of mutation; therefore, test results may not be a straightforward positive or negative^18,45

Solutions to BRCA1/2 Testing Challenges Focus on Tissue Sample Quality and Standardization^51,52

Implement germline BRCA1/2 testing for appropriate patients with breast cancer, considering guidance from NCCN^®, ASCO-SSO and ASBrS.